Lixte Biotechnology Holdings Inc., a clinical stage pharmaceutical company, has announced that new clinical findings have been published in the scientific journal Nature, validating its ongoing trials for Ovarian and Colorectal cancers using the proprietary compound LB100. The study, led by Dr. Amir Jazaeri at MD Anderson Cancer Center, revealed that inactivating mutations in PPP2R1A are linked to improved survival outcomes for patients treated with immune checkpoint blockade therapy. These mutations enhance the interferon gamma response pathway, correlating with improved immune checkpoint responses. Lixte is currently conducting trials in collaboration with GSK and Roche to test LB100 in combination with immunotherapies for ovarian and colon cancer patients. The company anticipates releasing the first results from these clinical studies in the latter half of this year.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。